Combination immunotherapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two immunotherapy drugs (IMM2510 and IMM27M) for advanced liver cancer. The goal is to see if this combination is safe and effective in shrinking tumors and helping people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of liver cancer (hepatocellular carcinoma).
- You should be up and about (able to care for yourself and do daily activities).
- Your liver, kidneys, and blood counts must be within acceptable levels (checked by tests).
- You must not have had another cancer in the last 5 years (with some exceptions).
- You must not have cancer that has spread to the brain with symptoms or to the lining of the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) with standard chemotherapy (gemcitabine and cisplatin) for a rare type of liver cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.